Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform

Oncolytic viruses (OVs) have been shown to induce anti-cancer immunity and enhance cancer immunotherapies, such as immune checkpoint inhibitor therapies. OV therapies can be further improved by arming OVs with immunostimulatory molecules, including various cytokines or chemokines. Here, we have deve...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Mol Ther Oncolytics
Autors principals: Ylösmäki, Erkko, Ylösmäki, Leena, Fusciello, Manlio, Martins, Beatriz, Ahokas, Petra, Cojoc, Hanne, Uoti, Arttu, Feola, Sara, Kreutzman, Anna, Ranki, Tuuli, Karbach, Julia, Viitala, Tapani, Priha, Petri, Jäger, Elke, Pesonen, Sari, Cerullo, Vincenzo
Format: Artigo
Idioma:Inglês
Publicat: American Society of Gene & Cell Therapy 2021
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7917457/
https://ncbi.nlm.nih.gov/pubmed/33718594
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.omto.2021.02.006
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars